Innovative ligands for nuclear receptors to eradicate cancer relapse

点击翻译按钮获取中文摘要

The aim of the "eRaDicate" international, multidisciplinary, and intersectoral cancer drug research and development programme is toempower 10 young scientists to become specialists in cancer research and drug development, while developing new therapiesagainst cancer stem cell-driven relapse and metastasis. Nuclear receptors, such as retinoic acid receptor (RAR) and vitamin D receptor(VDR), play key roles in many hallmarks of cancer and constitute effective targets for modern cancer therapy.To address the EU priority "Mission Cancer", we will 1) test the anti-cancer activity of RAR and VDR targeting compounds; 2) designand synthesise a highly innovative dual action hybrid compound acting simultaneously as RARgamma antagonist and VDR agonist; 3)devise pre-formulation strategies for our compounds; 4) and develop a novel, deep learning-based cancer analysis and diagnosticsmethod.We will test how our RAR and VDR-targeting compounds affect stemness and metastatic potential in leukaemia, breast, prostate,colorectal, and ovarian cancer. In parallel, we will assess if the pan-RAR antagonist is effective against chemotherapy-inducedneutropenia. For the development of the RAR and VDR targeting compounds into administrable medicines, ready for eventualcommercialisation, we will develop pre-formulation strategies. We will generate a novel and highly innovative label-free imageanalysis method based on histoplasmonic cytometry. The project will have lasting scientific, economic, and societal impact.In order to be prepared for a wide spectrum of career opportunities, we will train the doctoral candidates (DCs) not only to performoriginal and independent research on an internationally competitive level, but also endow them with creative, critical andentrepreneurial mindset, coupled with persistence in following their objectives.Our consortium consists of 8 academic and 1 industrial beneficiary, as well as 12 associated partners to provide training andsecondments.